Showing results (281-290 of 395) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Stephan Stilgenbauer, et al.Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.Molecular Systems Biology|May 24, 2019
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networksJan-Philipp Mallm, Murat Iskar, Naveed Ishaque, et al.Cell Death & Disease|July 31, 2019
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signalingFelix Seyfried, Salih Demir, Rebecca Louise Hörl, et al.Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.Blood|March 25, 2020
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxEugen Tausch, Christof Schneider, Sandra Robrecht, et al.The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Pageof 40